BPI
LGND icon

BFC Planning, Inc.’s Ligand Pharmaceuticals LGND Stock Holding History

BFC Planning, Inc.’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.81K Hold
9
– – ﹤0.01% 2908
2026
Q2 		$2.84K Hold
9
– – ﹤0.01% 2891
2026
Q1 		$1.8K Sell
9
-1
-10% -$198 ﹤0.01% 2616
2025
Q4 		$1.89K Buy
+10
New +$1.92K ﹤0.01% 2650

Other funds holding LGND

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

BFC Planning, Inc.'s LGND Position: Q3 2026 in Review

BFC Planning, Inc. held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 9 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

BFC Planning, Inc. first reported a position in LGND in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.84K in Q2 2026. 342 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • BFC Planning, Inc. held 9 shares of Ligand Pharmaceuticals worth $2.81K as of Q3 2026.
  • BFC Planning, Inc. left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q3 2026, its #2908 holding.
  • BFC Planning, Inc. first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • BFC Planning, Inc.'s Ligand Pharmaceuticals position peaked at $2.84K in Q2 2026.
  • 342 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on BFC Planning, Inc.'s 13F filing for Q3 2026, filed 13 Nov 2026.